Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 4Neoplasms 2Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Hamartoma Syndrome, Multiple 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Diseases 1Advanced Solid Tumor 1

Interventions

Temozolomide 6Cyclophosphamide 4antineoplaston AS 2-1 3antineoplaston A10 3Radiotherapy 3Filgrastim 3sargramostim 2aldesleukin 2Vincristine 2Thalidomide 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Irinotecan 2Donepezil 2Cisplatin 2Carmustine 2Bevacizumab 2veliparib 1trametinib 1temsirolimus 1surufatinib 1spartalizumab 1sonidegib 1ribociclib 1reolysin 1plerixafor 1ganitumab 1fosbretabulin 1entinostat 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroectodermal Tumors, Primitive × dactolisib × Clear all
NCT01658436 2016-05-02

BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.

Novartis

Phase 2 Completed
31 enrolled 7 charts

Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡